



ABN 53 075 582 740

ASX ANNOUNCEMENT 15 October 2010

Bionomics Limited (ASX:BNO) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today. Resolution 4, relating to the issue of share options to Dr Deborah Rathjen, was withdrawn from the meeting.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 14 September 2010.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy votes			
			For	Against	Open	Abstain
1	Adoption of Remuneration Report	Passed on a show of hands	140,477,951	322,027	1,059,717	583,194
2	Re-election of Non-Executive Director - Dr Errol De Souza	Passed on a show of hands	140,302,966	52,432	2,025,758	61,733
3	Approval of Proposed Issue of Share Options to Mr Christopher Fullerton	Passed on a show of hands	134,314,434	2,098,410	632,160	4,939,622

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Mr Trevor Thiele
CFO & Company Secretary
+618 835 46107 / 0418 848 703
tthiele@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders based on BNC210 which exhibits strong anxiolytic activity without side effects in preclinical models. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit www.bionomics.com.au

